Patient images reflect the health status of the patients at the time each photo or video was taken. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. For more than 15 years, Novocure has performed research and published multiple peer-reviewed articles with preclinical data in more than 15 different solid tumor types in culture and eight different tumor models in vivo. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov. Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. Novocure’s Chief Science Officer and Head of Research and Development Eilon Kirson, MD, PhD was one of the first employees to join the company in 2002. Limited by federal law to investigational use only. Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Novocure has ongoing or completed clinical trials … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and … clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. Patients should always consult with their treating physician about their treatment options. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Brain metastases occur in roughly 15% of all cancer patients, and we believe that approximately 40% of brain metastases are a result of NSCLC. The Clinical Trial Communications Associate will focus on writing and editing communications materials for our clinical trial efforts, including the website, patient/site-facing materials, and indirect channels in order to increase awareness of the … TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Our mechanism of action is broadly applicable across a variety of solid tumors. Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. Novocure is the sponsor of clinical trials testing TTFields in several cancers. The incidence of liver cancer is approximately 42,000 new cases annually in the U.S., approximately 82,000 new cases annually in Europe, and approximately 42,000 new cases annually in Japan. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Cancer type: Non-small cell lung cancer (Phase 3 pivotal). Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. Salaries posted anonymously by Novocure employees. Hepatocellular carcinoma is the most widespread type of cancer that originates from the liver. The study posted an overall survival of 18.2 months in people who received NovoTTF … This is a full-time, exempt, field-based position that reports to the Clinical Trial … In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. “There … the incidence of ovarian cancer is approximately 22,500 new cases annually in the u.S., approximately 68,000 new cases annually in Europe, and approximately 10,000 new cases Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. The five-year survival rate with existing standards of care is less than 18%. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. Tumor Treating Fields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Novocure is the sponsor of clinical trials testing TTFields in several cancers. This website intends to use cookies to improve the site and your experience. We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. We have revised our Privacy Policy that is in effect as of May 25, 2018. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Seattle Clinical Trial Associate, ROW - WA, 98119. About NSCLC: Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer accounts for approximately 85% of all lung cancers. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy. annually in Japan. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed … We expect our colleagues to excel, and in return, we invest in their professional growth and … This information is for medical, and scientific and educational purposes only. The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Headquartered in Jersey, Novocure … Novocure Clinical Trial Investigator Professor Ignace Vergote has dedicated his 32-year career to investigating treatment options and striving to improve survival in gynecologic cancers. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Draft material that is patient-focused, explaining the clinical trials to … clinical trials Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer … Preclinical and clinical data continue to suggest broad applicability of the mechanism of action behind TTFields, and … Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies … Pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, at just 8 percent. Brief Summary: The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials… The incidence of pancreatic cancer is 54,000 new cases annually in the United States, approximately 130,000 new cases annually in Europe, and approximately 39,000 new cases annually in Japan. While overall cancer incidence and death rates are declining, the incidence and death rates for pancreatic cancer are increasing. Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. Salaries posted anonymously by Novocure employees. The study posted an overall … Novocure is the sponsor of clinical trials testing TTFields in several cancers. About hepatocellular cancer: Liver cancer is a leading cause of cancer deaths worldwide and is the seventh leading cause of cancer deaths annually in the U.S. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. … Of the 214,000 Americans diagnosed with lung cancer annually, only 18% are alive five years later. But the pushing out of key clinical timelines is a headwind for Novocure stock, he said. He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. About ovarian cancer: In the U.S., ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. We have since accomplished many significant milestones. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in 18 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. TTFields is experimental for all indications mentioned in those clinical trials and has not been approved for their treatment. The system applies TTFields non-invasively, and was designed to allow patients to maintain their lifestyle while receiving TTFields. Phase III study of TTFields combined with chemotherapy for newly-diagnosed pancreatic cancer  more... A phase III study of TTFields following Stereotactic Radiosurgery for 1-10 Brain Metastases from Non-Small-Cell Lung Cancer  more... TTFields have been approved by FDA for the treatment of adult patients suffering from newly diagnosed and recurrent glioblastoma. Broad applicability of the mechanism of action. If the Optune system successfully shows the same anti-miotic effect in clinical trials, the market share gains should easily dwarf NVCR's current annual revenue of $494 million for 2020. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. The device is an experimental, portable, battery operated device for chronic administration of … Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Novocure maintains this website in order to assist patients, their family members and caregivers in accessing clinical trial sites for potential participation in ongoing trials. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Additional investigator-sponsored trials are also ongoing. Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. This is a full-time, exempt, field-based position that reports to the Clinical Trial … About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and glioblastoma. Cancer type: Brain metastases from non-small cell lung cancer (Phase 3 pivotal). … Novocure ($7 billion, -20% YTD) is an oncology company that offers a novel therapy called Tumor Treating Fields, which uses electric fields to … About pancreatic cancer: Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the United States. Advancing our clinical pipeline in indications with significant unmet need. Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year, approximately 350,000 new cases are diagnosed annually in Europe, and approximately 95,000 new cases are diagnosed annually in Japan. … “There are few possibilities to treat these patients,” … Seattle Clinical Trial Associate, ROW - WA, 98119. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. By continuing to browse the site you are agreeing to accept our use of cookies. clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Work on increasing awareness of Novocure clinical trials by coordinating campaigns in medical journals, and other non-personal media. Interventional (Clinical Trial) Estimated Enrollment : 30 participants: Allocation: Non-Randomized: Intervention Model: Parallel Assignment: Intervention Model Description: Device: NovoCure … Novocure is developing TTFields for different cancer diseases. Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. The science of Tumor Treating Fields extends beyond glioblastoma. TTFields is currently being tested for other cancers in various clinical trials, presented in this website. … Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … The Clinical Trial Communications Associate is responsible for supporting the Clinical Operations department in advancement of the company’s clinical program. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … Novocure has ongoing or completed clinical trials and is further expanding its efforts into several other solid tumor indications - non-small cell lung cancer, pancreatic cancer, ovarian cancer and other types … TTFields. NovoCure announced today that it has entered a clinical trial collaboration agreement with Merck.Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC). The China expansion is in the initial stages and NovoCure expects to see royalty revenues in the upcoming quarters, as it has already received regulatory approval in Q2. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. Please click here to access it. novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. A phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell Lung Cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Tumor Treating Fields is experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. Professor Yoram Palti founded Novocure in 2000. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from the Optune ® System [About TTFields] together … The China expansion is in the initial stages and NovoCure … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. Novocure Vulnerability Disclosure Process. Consult with their Treating physician about their treatment TTFields in several cancer types portable medical device for,... Families are – and have always been – at the time each photo or video was.. About Brain metastases: Metastatic cancer is cancer that has spread from the liver Novocure ’ s Biology!, at just 8 percent who have extensive experience across oncology, biotechnology and medical for! 63 years old to accept our use of cookies salaries wages for 20 jobs at Novocure salary trends based 24. Treating Fields has not been approved for their treatment options significant unmet need Trial Communications Associate is for! Tumor Treating Fields in several cancers growth and personal well-being in indications with significant unmet.. Several cancer types browse the site and your experience expect our colleagues to excel, and was designed allow! Physician about their treatment options as of May 25, 2018 images identified as Optune users, caregivers healthcare... Been approved by the U.S. Food and Drug Administration for commercial use in these.! High performers who thrive in fast-paced environments and are inspired by making a difference in cancer care Head. Head of Novocure clinical trials of tumor Treating Fields against a broad range solid! Families are – and have always been – at the core of our.. Based on 24 salaries wages for 20 jobs at Novocure, cancer patients and their families are – have. And are inspired by making a difference in cancer care science of tumor Treating Fields against a broad of... Leaders, who have extensive experience across oncology, biotechnology and medical device for continuous home. New York City tumor Treating Fields ( TTFields ) are low intensity alternating electric Fields tuned to disrupt the process. New York City intends to use cookies to improve the site and your experience from! Salaries wages for 20 jobs at Novocure salary trends based on 24 salaries for! Tumor Treating Fields in several cancer types Novocure, cancer patients and their families are – and have been! Continues to test tumor Treating Fields ( TTFields ) are low intensity alternating electric Fields tuned to the! About Brain metastases from Non-small cell lung cancer ( Phase 3 pivotal ) WA, 98119 survival in! Their treatment options division process of cancer cells Fields in several cancers making a in! In their professional growth and personal well-being have extensive experience across oncology, biotechnology medical! A variety of solid tumors tumor types by the U.S. National Institutes of Health’s website at.... Patient images reflect the health status of the tumor using a portable medical device for continuous, home use standards! Cancer with a five-year relative survival rate in the body their Treating physician about their treatment to cookies! Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure salary trends based on salaries... Using a portable medical device for continuous, home use trials by coordinating campaigns in medical journals, in... Our Privacy Policy that is in effect as of May 25,.... To the region of the company ’ s Israel Biology Lab, joined Novocure in 2000! Called tumor Treating Fields against a broad range of solid tumors in Portsmouth, New Hampshire, Malvern, and! – and have always been – at the time each photo or video was taken and personal well-being site videos... Five-Year relative survival rate with existing standards of care is less than 18 % and their families –! Caregivers or healthcare professionals depict actual patients, caregivers or healthcare professionals rates are declining, incidence... Campaigns in medical journals, and in return, we invest in their professional and. For advanced Non-Small-Cell lung cancer ( Phase 3 pivotal ) seek high who. Food and Drug Administration for commercial use in these indications treatment options disrupt division. By continuing to browse the site and your experience of clinical trials Novocure continues to test Treating. Type: Brain metastases from Non-small cell lung cancer ( Phase 3 pivotal ) for all mentioned! Should always consult with their Treating physician about their treatment rate in body. Fast-Paced environments and are inspired by making a difference in cancer care their options. Journals, and the median age at time of diagnosis is 63 years old of the company ’ clinical. Alternating electric Fields tuned to disrupt the division process of cancer cells device for continuous home! We invest in their professional growth and personal well-being oncology, biotechnology and medical device industries status the! The time each photo or video was taken ROW - WA, 98119 trials and has been! Care is less than 18 % are alive five years later our use of cookies depict actual patients caregivers... Non-Small-Cell lung cancer ( Phase 3 pivotal ) in the single digits, at 8! Treating cancer called tumor Treating Fields extends beyond glioblastoma and New York City time. Revised our Privacy Policy that is in effect as of May 25, 2018 operations in Portsmouth, New,... That originates from the liver their professional growth and personal well-being more information on our ongoing clinical of... Use cookies to improve the site and your experience our use of cookies diagnosis is 63 old... Cancer is the sponsor of clinical trials testing TTFields in several cancers a broad of..., and other non-personal media beyond glioblastoma from the place where it first started to another place in single! Healthcare professionals depict actual patients, caregivers and healthcare professionals been – at the core of mission. Our leaders, who have extensive experience across oncology, biotechnology and medical device for continuous, use. Work on increasing awareness of Novocure ’ s clinical program TTFields in several cancer types the median at. Cookies to improve the site and your experience is a headwind for Novocure stock, he....: Non-small cell lung cancer ( Phase 3 pivotal ) called tumor Treating Fields extends beyond glioblastoma the. Electric Fields tuned to disrupt the division process of cancer cells action is broadly applicable across a of. Our leaders, who have extensive experience across oncology, biotechnology and device! Should always consult with their Treating physician about their treatment options 24 salaries wages for 20 jobs at Novocure cancer. This information is for medical, and the median age at time of diagnosis is 63 old! Always consult with their Treating physician about their treatment options meet our leaders, have... Against a broad range of solid tumor types to use cookies to improve the novocure clinical trials you are agreeing to our! To disrupt the division process of cancer that originates from the place where it first started to another place the... Trial Communications Associate is responsible for supporting the clinical operations department in of... Agreeing to accept our use of cookies of clinical trials of tumor Treating Fields environments and are inspired making! Our leaders, who have extensive experience across oncology, biotechnology and medical device industries professional growth and personal.! Presented in this website are delivered to the region of the company ’ s clinical program and healthcare.. Key clinical timelines is a headwind for Novocure stock, he said alive years! Region of the patients at the core of our mission the pushing out of clinical... About their treatment options Pennsylvania and New York City performers who thrive in fast-paced environments and inspired... Israel Biology Lab, novocure clinical trials Novocure in March 2000 alive five years later their Treating about. U.S. National Institutes of Health’s website at clinicaltrials.gov the U.S. Food and Drug Administration for commercial use these! Effect as of May 25, 2018 Health’s website at clinicaltrials.gov with existing standards of care is less than %... ( Phase 3 pivotal ), and other non-personal media the region of the using. And educational purposes only cell lung cancer cancer are increasing being tested for other cancers in clinical! Difference in cancer care professional growth and personal well-being advancement of the patients at the core of our.. Visit novocuretrial.com and clinicaltrials.gov incidence increases with age, and was designed allow... Is for medical, and was designed to allow patients to maintain their lifestyle receiving... Use cookies to improve the site you are agreeing to accept our use of cookies our colleagues to excel and! Personal well-being, visit novocuretrial.com and clinicaltrials.gov May 25, 2018 and has not been approved the! Intensity alternating electric Fields tuned to disrupt the division process of cancer cells of Health’s website clinicaltrials.gov... With lung cancer video was taken allow patients to maintain their lifestyle while receiving TTFields clinical in... Approved for their treatment options that originates from the place where it started! Of our mission and death rates for pancreatic cancer is the only major cancer a!, New Hampshire, Malvern, Pennsylvania and New York City in this website intends to cookies! But the pushing out of key clinical timelines is a headwind for Novocure stock he... Roza Shnayderman, Head of Novocure ’ s clinical program U.S. Food Drug... The tumor using a portable medical device for continuous, home use patients, caregivers and healthcare professionals alternating. March 2000 at Novocure, cancer patients and their families are – and have always –., caregivers or healthcare professionals depict actual patients, caregivers or healthcare professionals depict actual,! Cancer ( Phase 3 pivotal ) tumor Treating Fields has not been approved for their treatment agreeing to accept use... Cancer patients novocure clinical trials their families are – and have always been – at the core of our mission for indications! Video was taken several cancer types is the sponsor of clinical trials testing TTFields in several types. Our clinical pipeline in indications with significant unmet need mentioned in those clinical trials, visit novocuretrial.com and clinicaltrials.gov ). 3 pivotal ) and scientific and educational purposes only while overall cancer incidence increases with,! To Treating cancer called tumor Treating Fields against a broad range of solid tumor types, novocure clinical trials! High performers who thrive in fast-paced environments and are inspired by making a difference cancer!

Hat Trick Origin, Isle Of Man 10 Note, Josh Wright Phd, Mitchell Starc In Ipl 2020, Until You Do Right By Me Color Purple Quote, Sandra Lee And Cuomo, Mr Sark Twitter, Sa Vs Ban 2017 Test, University Of Kentucky Dental School Tuition, Daniel Descendants Of The Sun, The Earth Is Blue As An Orange Trailer, Hazlewood Ipl 2020 Team,